Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs

[1]  J. LoPiccolo,et al.  Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy , 2008, Autophagy.

[2]  S. Patterson,et al.  Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy , 2010, Journal of Virology.

[3]  J. Arrowsmith.  Trial watch: Phase III and submission failures: 2007–2010 , 2011, Nature Reviews Drug Discovery.

[4]  J. Menéndez,et al.  Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Bhattacharya,et al.  In vitro activity of artemisinin in combination with clotrimazole or heat-treated amphotericin B against Plasmodium falciparum. , 2008, The American journal of tropical medicine and hygiene.

[6]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[7]  Manish Sud,et al.  Computational Modeling of Kinase Inhibitor Selectivity. , 2010, ACS medicinal chemistry letters.

[8]  S James Matthews,et al.  Thalidomide: a review of approved and investigational uses. , 2003, Clinical therapeutics.

[9]  W. Figg,et al.  Thalidomide, an antiangiogenic agent with clinical activity in cancer. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[11]  S. Fabro,et al.  Toxicity and Teratogenicity of Optical Isomers of Thalidomide , 1967, Nature.

[12]  J. DiMasi,et al.  Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.

[13]  F. Petitet,et al.  Drug repositioning using in silico compound profiling. , 2009, Future medicinal chemistry.

[14]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[15]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[16]  Philip E. Bourne,et al.  SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison , 2010, Nucleic Acids Res..

[17]  T. Scior,et al.  Application of drug repositioning strategy to TOFISOPAM. , 2008, Current medicinal chemistry.

[18]  J. Stockman.  Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome , 2011 .

[19]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[20]  A. Coghlan,et al.  One drug, six men, disaster... , 2006, New scientist.

[21]  Louis A Tartaglia.  Complementary new approaches enable repositioning of failed drug candidates , 2006, Expert opinion on investigational drugs.

[22]  Clara Campas,et al.  Drug repositioning summit: finding new routes to success. , 2009, Drug news & perspectives.

[23]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[24]  E. Tobinick.  The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[25]  R Abagyan,et al.  Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs , 2007, Proceedings of the National Academy of Sciences.

[26]  R. D'Agostino.  Changing end points in breast-cancer drug approval--the Avastin story. , 2011, The New England journal of medicine.